Alvarez Ralph 4

What Happened
Ralph Alvarez, a director of Eli Lilly & Co. (LLY), was granted 10.995 shares (reported as stock units) on 2026-06-15 at a per-share valuation of $1,129.35, a total value of $12,417. The filing shows these shares were elected to be deferred in lieu of cash compensation and will be settled in Lilly common stock after Mr. Alvarez’s separation from service.

Key Details

• Transaction date: 2026-06-15; Filing date: 2026-06-16 (timely filing).
• Transaction type/code: Award/Grant (A).
• Shares/units acquired: 10.995; Price/valuation per share: $1,129.35; Total reported value: $12,417.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: (1) The shares were deferred under the Lilly Directors' Deferral Plan and will be settled in shares after separation from service. (2) The reporting person disclaims beneficial ownership except for his pecuniary interest.
• No indication this was a market purchase or sale—this is routine director compensation, not an open-market trade.

Context
Deferred stock unit awards are a common form of director compensation and are typically settled into actual shares upon the director’s departure; they do not represent an immediate purchase or sale in the open market. Such grants are routine and should be interpreted as compensation rather than a direct signal of personal buying or selling conviction.